835 related articles for article (PubMed ID: 23400000)
1. Development of PI3K inhibitors: lessons learned from early clinical trials.
Rodon J; Dienstmann R; Serra V; Tabernero J
Nat Rev Clin Oncol; 2013 Mar; 10(3):143-53. PubMed ID: 23400000
[TBL] [Abstract][Full Text] [Related]
2. Status of PI3K/Akt/mTOR pathway inhibitors in lymphoma.
Westin JR
Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):335-42. PubMed ID: 24650973
[TBL] [Abstract][Full Text] [Related]
3. Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway.
Martelli AM; Evangelisti C; Chappell W; Abrams SL; Bäsecke J; Stivala F; Donia M; Fagone P; Nicoletti F; Libra M; Ruvolo V; Ruvolo P; Kempf CR; Steelman LS; McCubrey JA
Leukemia; 2011 Jul; 25(7):1064-79. PubMed ID: 21436840
[TBL] [Abstract][Full Text] [Related]
4. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway.
Polivka J; Janku F
Pharmacol Ther; 2014 May; 142(2):164-75. PubMed ID: 24333502
[TBL] [Abstract][Full Text] [Related]
5. Targeting PI3K in cancer: mechanisms and advances in clinical trials.
Yang J; Nie J; Ma X; Wei Y; Peng Y; Wei X
Mol Cancer; 2019 Feb; 18(1):26. PubMed ID: 30782187
[TBL] [Abstract][Full Text] [Related]
6. mTOR pathway inhibitors in cancer therapy: moving past rapamycin.
Wacheck V
Pharmacogenomics; 2010 Sep; 11(9):1189-91. PubMed ID: 20860456
[No Abstract] [Full Text] [Related]
7. Molecular alterations of PI3K/Akt/mTOR pathway: a therapeutic target in endometrial cancer.
Pavlidou A; Vlahos NF
ScientificWorldJournal; 2014; 2014():709736. PubMed ID: 24526917
[TBL] [Abstract][Full Text] [Related]
8. PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside.
Alzahrani AS
Semin Cancer Biol; 2019 Dec; 59():125-132. PubMed ID: 31323288
[TBL] [Abstract][Full Text] [Related]
9. Higher Risk of Infections with PI3K-AKT-mTOR Pathway Inhibitors in Patients with Advanced Solid Tumors on Phase I Clinical Trials.
Rafii S; Roda D; Geuna E; Jimenez B; Rihawi K; Capelan M; Yap TA; Molife LR; Kaye SB; de Bono JS; Banerji U
Clin Cancer Res; 2015 Apr; 21(8):1869-76. PubMed ID: 25649020
[TBL] [Abstract][Full Text] [Related]
10. Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway.
Burris HA
Cancer Chemother Pharmacol; 2013 Apr; 71(4):829-42. PubMed ID: 23377372
[TBL] [Abstract][Full Text] [Related]
11. Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development.
Zhao HF; Wang J; Shao W; Wu CP; Chen ZP; To ST; Li WP
Mol Cancer; 2017 Jun; 16(1):100. PubMed ID: 28592260
[TBL] [Abstract][Full Text] [Related]
12. New inhibitors of the mammalian target of rapamycin signaling pathway for cancer.
Albert S; Serova M; Dreyer C; Sablin MP; Faivre S; Raymond E
Expert Opin Investig Drugs; 2010 Aug; 19(8):919-30. PubMed ID: 20569080
[TBL] [Abstract][Full Text] [Related]
13. Dueling for dual inhibition: Means to enhance effectiveness of PI3K/Akt/mTOR inhibitors in AML.
Herschbein L; Liesveld JL
Blood Rev; 2018 May; 32(3):235-248. PubMed ID: 29276026
[TBL] [Abstract][Full Text] [Related]
14. Defining biomarkers to predict sensitivity to PI3K/Akt/mTOR pathway inhibitors in breast cancer.
Gonzalez-Angulo AM; Blumenschein GR
Cancer Treat Rev; 2013 Jun; 39(4):313-20. PubMed ID: 23218708
[TBL] [Abstract][Full Text] [Related]
15. [PI3K-AKT-mTOR pathway inhibitors].
Cortot A; Armand JP; Soria JC
Bull Cancer; 2006 Jan; 93(1):19-26. PubMed ID: 16455502
[TBL] [Abstract][Full Text] [Related]
16. Targeting the PI3-kinase/Akt/mTOR signaling pathway.
Hassan B; Akcakanat A; Holder AM; Meric-Bernstam F
Surg Oncol Clin N Am; 2013 Oct; 22(4):641-64. PubMed ID: 24012393
[TBL] [Abstract][Full Text] [Related]
17. Targeting the PI3K/AKT/mTOR pathway: biomarkers of success and tribulation.
Owonikoko TK; Khuri FR
Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714559
[TBL] [Abstract][Full Text] [Related]
18. Targeting the PI3K-AKT-mTOR signaling network in cancer.
Khan KH; Yap TA; Yan L; Cunningham D
Chin J Cancer; 2013 May; 32(5):253-65. PubMed ID: 23642907
[TBL] [Abstract][Full Text] [Related]
19. The PI3K/Akt/mTOR pathway in ovarian cancer: therapeutic opportunities and challenges.
Cheaib B; Auguste A; Leary A
Chin J Cancer; 2015 Jan; 34(1):4-16. PubMed ID: 25556614
[TBL] [Abstract][Full Text] [Related]
20. Phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway inhibition: a breakthrough in the management of luminal (ER+/HER2-) breast cancers?
Zardavas D; Fumagalli D; Loi S
Curr Opin Oncol; 2012 Nov; 24(6):623-34. PubMed ID: 22960556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
